Nebulized fentanyl for refractory dyspnea secondary to chronic obstructive pulmonary disease (COPD): A case report

Leah Hildreth, Danielle Pett, Elizabeth Higgins, Leah Hildreth, Danielle Pett, Elizabeth Higgins

Abstract

We present a case where we evaluated the effectiveness of nebulized fentanyl in the treatment of refractive dyspnea in a patient with chronic obstructive pulmonary disease (COPD) with major complications and comorbidities. Nebulized fentanyl was used to successfully decrease the subjective symptoms of refractory dyspnea in this given patient. Nebulized fentanyl appears to be a cost-effective treatment option in patients that experience episodes of severe shortness of breath (SOB).

Keywords: COPD; Dyspnea; Nebulized fentanyl.

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

© 2020 Published by Elsevier Ltd.

References

    1. Parshall M.B., Schwartzstein R.M., Adams L. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 2012;185(4):435–452.
    1. Uronis H., Currow D., Abernethy A. Palliative management of refractory dyspnea in COPD. Chron Obstruct Pulmon Dis. 2006;1(3):289–304.
    1. Blinderman C., Homel P., Billings J. Symptom distress and quality of life in patients with advanced chronic obstructive pulmonary disease. J. Pain Symptom Manag. 2009;38:115–123.
    1. Lozano R., Naghavi M., Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
    1. Afolabi T.M., Nahata M.C., Pai V. Nebulized opioids for the palliation of dyspnea in terminally ill patients. Am. J. Health Syst. Pharm. 2017;74(14):1053–1061.
    1. Benyamin R., Trescot A.M., Datta S. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–S120.
    1. Krajnik M., Jassem E., Sobanski P. Opioid receptor bronchial tree: current science. Curr. Opin. Support. Palliat. Care. 2014;8(3):191–199.
    1. Boyden J.Y., Connor S.R., Otolorin L. Nebulized medications for the treatment of dyspnea: a literature review. J. Aerosol Med. Pulm. Drug Deliv. 2015;28(1):1–19.
    1. Coyne P.J. The use of nebulized fentanyl for the management of dyspnea. Clin. J. Oncol. Nurs. 2003;7(3):334–335.
    1. Soffler M., Rose A., Hayes M.M. Treatment of acute dyspnea with morphine to avert respiratory failure. Ann Am Thorac Soc. 2017;14(4):584–588.
    1. Nagel M.W., Doyle C.C., Bates S.L. Monaghan Medical Corporation ©; 2006. Nebulizer Dose Comparison : Aerosol Laboratory Report.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner